Nihon Kohden (TSE:6849) Could Be 24% Undervalued On Weak First Quarter Results

Nihon Kohden (TSE:6849) recently reported first quarter results that showed sales of ¥47,405 million compared with ¥50,020 million a year earlier, and a shift from ¥137 million net income to a ¥756 million net loss.

See our latest analysis for Nihon Kohden.

Against this weaker quarter, the share price of Nihon Kohden has also lost ground, with a year-to-date share price return of a 13.10% decline and a 1-year total shareholder return of a 9.67% decline, pointing to fading momentum as investors reassess earnings risk.

If you are considering how to position around medical technology and diagnostics, this is a good moment to widen your search and review 7 healthcare AI stocks

Nihon Kohden’s weaker quarter and sliding share price leave an obvious tension. Has most of the downside already played out, or is the stock still pricing in more upside than the latest numbers support?

Price to earnings for Nihon Kohden, is the discount justified?

Nihon Kohden is trading on a P/E of 17.3x, which screens as good value against both its own estimated fair ratio and the wider peer group average.

The P/E ratio compares the current share price with earnings per share, so it reflects what the market is willing to pay for each unit of current profit. For a medical equipment company like Nihon Kohden, this is a useful shorthand for how investors weigh its earnings profile, stability and modest forecast growth.

Here, the stock trades on a P/E of 17.3x compared with a peer average of 41.6x, while the fair P/E derived from the SWS model is 19.7x. That combination signals a material discount to companies in the same industry and also to the level the fair ratio analysis suggests the multiple could move toward if sentiment were to normalise.

Explore the SWS fair ratio for Nihon Kohden

Result: Price-to-earnings of 17.3x (UNDERVALUED)

However, there are still clear risks if earnings soften again, or if the share price decline of recent years reflects deeper concerns about Nihon Kohden’s growth profile.

Find out about the key risks to this Nihon Kohden narrative.

Another view of Nihon Kohden using fair value estimates

While the P/E suggests Nihon Kohden looks inexpensive, the SWS fair value estimate based on future cash flows points to a different anchor. The shares trade around ¥1,472.5, compared with an estimated fair value of ¥1,943.89, which implies a 24.2% discount.

That result also aligns with the conclusion that the stock is trading below an estimate of future cash flow value. If you put more weight on the SWS DCF model than on simple earnings multiples, it raises a question: Is the current price a reflection of cautious sentiment or an opening for patient investors?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nihon Kohden for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 27 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Nihon Kohden looking mixed, it helps to move quickly and test the numbers yourself rather than rely on headlines alone. To see what investors are optimistic about in the current setup, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Nihon Kohden?

Do not stop with Nihon Kohden. Use this moment to broaden your watchlist and line up a few fresh ideas that match your risk and income goals.

• Target dependable cash generators by scanning companies with resilient finances through the solid balance sheet and fundamentals stocks screener (41 results).
• Hunt for potential value opportunities by reviewing the 27 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Strengthen your income focus by checking out the 34 dividend fortresses that aim to pair higher yields with financial robustness.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com